BMY vs REGN: stock comparison and AI forecast
Bristol Myers Squibb Co (BMY) and Regeneron Pharmaceuticals, Inc. (REGN) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
BMY Bristol Myers Squibb Co
- Price
- $61.71 +8.4% · 6M
- Market Cap
- $126.14B
- P/E Ratio
- 13.7x
- Size
- large-cap
- AI Forecast
REGN Regeneron Pharmaceuticals, Inc.
- Price
- $961.26 +35.5% · 6M
- Market Cap
- $100.21B
- P/E Ratio
- 21.6x
- Size
- large-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Six-month price performance
Closing prices rebased to 100 at the start of the window.
Key facts
- BMY is 1.3 times larger than REGN by market capitalization ($126.14B against $100.21B).
- BMY trades at 13.7 times trailing earnings, REGN at 21.6 times.
- Over the last six months REGN returned +35.5% and BMY +8.4%.
- REGN turns 36.5% of its revenue into net income, against 18.5% for BMY.
- BMY carries 2.79 times debt per unit of equity, against 0.33 times for REGN.
- BMY yields 4.06% in dividends and REGN 0.38%.
- Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | BMY | REGN |
|---|---|---|
| Market Cap | $126.14B | $100.21B |
| P/E Ratio | 13.65x | 21.55x |
| P/B Ratio | 5.39x | 2.99x |
| Dividend Yield | 4.06% | 0.38% |
| EPS | $4.52 | $45.18 |
| Book Value/Share | $11.45 | $325.37 |
| Revenue/Share | $24.48 | $164.11 |
| FCF/Share | $4.54 | $37.16 |
Profitability & Margins
| Metric | BMY | REGN |
|---|---|---|
| ROE | 39.5% | 18.4% |
| ROA | 10.4% | 13.9% |
| ROIC | – | 12.7% |
| Gross Margin | 69.2% | – |
| Operating Margin | – | 28.8% |
| Net Margin | 18.5% | 36.5% |
| EBT Margin | 22.6% | 33.6% |
| Tax Rate | 18.4% | 15.3% |
Financial Health
| Metric | BMY | REGN |
|---|---|---|
| Current Ratio | 1.59x | 3.35x |
| Quick Ratio | 1.44x | 2.89x |
| D/E Ratio | 2.79x | 0.33x |
| Financial Leverage | 3.79x | 1.33x |
| Interest Coverage | 42.5x | 21.1x |
| Working Capital | $11.01B | $14.59B |
Cash Flow
| Metric | BMY | REGN |
|---|---|---|
| Operating Cash Flow | $10.65B | $4.85B |
| Free Cash Flow | $9.29B | $3.83B |
| Capital Spending | -$1.37B | -$1.02B |
| OCF Growth YoY | -35.9% | -4.4% |
| FCF Growth YoY | -39.3% | -9.4% |
| FCF/Sales | 18.6% | 22.6% |
| CapEx/Sales | 2.7% | 6.0% |
Operational Efficiency
| Metric | BMY | REGN |
|---|---|---|
| Asset Turnover | 0.56x | 0.38x |
| Receivables Turnover | 5.4x | 2.2x |
| Inventory Turnover | 5.7x | – |
| Fixed Assets Turnover | 6.3x | 3.0x |
| Days Sales Outstanding | 67 days | 164 days |
| Days Inventory | 64 days | – |
| Payables Period | 110 days | – |
| Cash Conversion Cycle | 21 days | – |
Income Statement
| Metric | BMY | REGN |
|---|---|---|
| Total Revenue | $50.03B | $16.90B |
| Operating Income | – | $4.86B |
| Net Income | $9.24B | $6.17B |
| R&D Expense | $10.56B | $6.60B |
| SG&A Expense | $7.32B | $2.76B |
| Cost of Goods Sold | $15.39B | – |
Dividend & Shareholder Information
| Metric | BMY | REGN |
|---|---|---|
| Dividends Per Share | $2.50 | $3.72 |
| Payout Ratio | 55.3% | 8.2% |
| Shares Outstanding | 2044M | 103M |
| Net Income Growth | 53.1% | 220.3% |
| EPS Growth | 52.2% | 8.0% |
BMY vs REGN: stock comparison and AI forecast
Which is bigger, BMY or REGN?
BMY is 1.3 times larger than REGN by market capitalization ($126.14B against $100.21B).
Which is cheaper on earnings, BMY or REGN?
BMY trades at 13.7 times trailing earnings, REGN at 21.6 times.
Which stock performed better over the last six months, BMY or REGN?
Over the last six months REGN returned +35.5% and BMY +8.4%.
Which one does Intratio's AI model rank higher, BMY or REGN?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.